| 1/15 | US=18 / Tese/FAP Kaiano JHL. Correlação entre o polimorfismo do códon 72 do gene P53 e a presença de DNA de papilomavírus humano (HPV) em carcinoma de pênis. São Paulo, 2000. 73 p. Dissertação(Mestrado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2000/us18.pdf NEOPLASIAS PENIANAS. FATOR DE RISCO; PAPILOMAVIRUS HUMANO. BIOLOGIA; POLIMORFISMO; GENE P53 |
| 2/15 | US=22 / Urologia Garcia JA, Varizi SJA, Ganapathi R. Proteasome-NFkB signaling pathway: relevance in RCC. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 305-20. ISBN 978-1-58829-737-2. SISTEMA UBIQUITINA-PROTEASSOMA; VIA DE PROTEASSOMA NA RCC; INIBICAO DO PROTEASSOMA |
| 3/15 | US=8 / Laboratório Lecker SH, Saric T, Goldberg AL. Protein degradation in cells. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone, 2009. p. 34-41. ISBN 978-0-443-06715-0. DEGRADACAO DE PROTEINAS; PROTEOLISE LISOSSOMAL; CONJUGACAO DA UBIQUITINA; INIBIDORES DE PROTEASSOMA; TERAPIA DO CANCER; DEGRADACAO ASSOCIADA AO RETICULO ENDOPLASMATICO; PROTEOLISE EM MITOCONDRIA; QUEBRA DE PROTEINA MUSCULAR; CAQUEXIA |
| 4/15 | US=47 / Câncer Toyota M, Kashima L, Tokino T. CHFR as a potential anticancer target. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 163-76. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CHFR; AGENTE ANTICANCERIGENO; CHECKPOINT MITOTICO; CHECKPOINT PROFASE; TUBULINA; UBIQUITINA LIGASE E3; MITOSE |
| 5/15 | US=58 / Câncer Alao JP. G1 phase cyclins in cancer development and progression. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 123-53. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FASE G1; CICLINAS EM CANCER; CICLO CELULAR; FASE G1; CICLINA D1; CICLINA E; CANCER; ONCOGENE; UBIQUITINA; PROTEASSOMA 26S; TERAPIA DO CANCER |
| 6/15 | US=84 / Biol/Mol Zhang YE, Yamashita M. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: transforming growth factor-B in cancer therapy: smurfs in TGF-B signaling and regulation of bone homeostasis and cancer. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 155-67. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. |
| 7/15 | US=84 / Biol/Mol Gold LI, Lecanda J. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: mechanisms of cell cycle regulation by TGF-B disabled in cancer. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 213-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. P27KIP1; CKS1; SKP2; CANCRO ENDOMETRIAL; UBIQUITINA-PROTEASSOMA |
| 8/15 | US=84 / Biol/Mol Band A, Laiho M. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: transforming growth factor-B in cancer therapy. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 243-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. TGF-BETA; SMAD; TRANSDUCAO DE SINAL; SNON; PROTEASSOMA; UBIQUITINA; SUMO; DEGRADACAO |
| 9/15 | US=84 / Biol/Mol Itoh S, Suzuki H, Itoh F, Miyazono K, Kato M. TGF-B in inflammation and fibrosis: negative regulation of the TGF-B family signal pathway by inhibitory smads and their involvement in cancer and fibrosis. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 649-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. |
| 10/15 | US=90 / Biol/Mol Carraway KL, Yen L, Ingalla E, Sweeney C. EGFR signaling networks: negative regulation of signaling by the EGFR family. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 169-86. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. RECEPTOR EGF; CANCER DE MAMA; ERBB2; REGULADOR NEGATIVO; UBIQUITINA LIGASE E3; CAMUNDONGOS TRANSGENICOS |
| 11/15 | US=2 / Biol/Mol Walczak H, Koschny R, Willen D, Schader MB, Sykora J, Ganten TM, Haas TL. Death receptor: the TRAIL receptor-ligand system: biochemistry of apoptosis induction, therapeutic potential for cancer treatment and physiological function. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 31-92. ISBN 978-3-527-31237-5. RECEPTOR MORTE; SISTEMA DE RECEPTOR-LIGANTE TRAIL; BIOQUIMICA DA INDUCAO DE APOPTOSE; POTENCIAL TERAPEUTICO; CANCER. TERAPIA; FUNCAO FISIOLOGICA; ATIVACAO DA CASPASE; FAMILIA BCL-2; UBIQUITINA; TERAPIA GENETICA; INFECCAO VIRAL; IMUNOPATOLOGIAS; DOENCAS AUTO-IMUNES; TRANSPLANTE ALOGENICO DE CELULAS-TRONCO HEMATOPOETICAS |
| 12/15 | US=36 / Patologia Schiffer D. The ubiquitin-proteasome system. In: ___. Brain tumor pathology: current diagnostic hotspots and pitfalls. The Netherlands: Springer, 2006. p. 183-7. ISBN 978-1-4020-3998-0. |
| 13/15 | US=120 / Câncer Saad STO, Pagnano KBB, Bigarella CL. Mecanismos de resistência a morte celular. In: Hoff PMG. Tratado de oncologia. São Paulo: Atheneu, 2013. p. 345-356. ISBN 85-388-0312-6. RELEVANCIA DAS VIAS P53 PARA O CANCER; RELEVANCIA DAS VIAS BCL-02 PARA O CANCER; REGULACAO E FUNCAO DA P53; DESREGULACAO DA VIA P53; RELACAO ENTRE P53 E VIAS DO BCL-2; DESREGULACAO DO BCL-2; RESISTENCIA INDUZIDA POR HIPOXIA; AUTOFAGIA COMO MECANISMO DE SOBREVIVENCIA; DESEQUILIBRIO EM QUINASES E FOSFATASES; SISTEMA UBIQUITINA PROTEASSOMA; QUINASES DEPENDENTES DE CICLINA |
| 14/15 | US=22-C / Câncer Kirk CJ, Tuch BB, Arastu-Kapur S, Boise LH. Inibidores de proteassoma. In: DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10 ed. Philadelphia: Wolters Kluwer, 2015. p. 258-262. ISBN 978-1-45119294-0. VIA DA UBIQUITINA PROTEOSSOMA. BIOQUIMICA; CLASSES QUIMICAS DE INIBIDORES DE PROTEASSOMA EM DESENVOLVIMENTO CLINICO; ATIVIDADE PRE-CLINICOS DE INIBIDORES DE PROTEASSOMA; INIBIDORES DE PROTEASSOMA EM CANCER; BIOMARCADORES DE INIBIDORES DE PROTEASSOMA |
| 15/15 | US=507 / Tese/FAP Rodrigues BR. Regulação da atividade de STAT3 e o papel da proteína STI1/Hop secretada em glioblastoma. [Regulation of STAT3 activity and the role of secreted STI1/Hop in glioblastoma]. São Paulo, 2014. 47 p. Tese(Doutorado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/Doutorado/2014/BrunaRoz/BrunaRoz.pdf GLIOBLASTOMA; ASTROCITOMA; FATOR DE TRANSCRICAO STAT3; EXOSSOMOS; STI1; HOP |
